Premier Pharmacy Labs Recalls Products Due to Sterility Concerns

News
Article

Premier Pharmacy Labs is voluntarily recalling multiple products because of the potential lack of sterility assurance.

Premier Pharmacy Labs announced on April 11, 2018 that it was voluntarily recalling products because of a potential lack of sterility assurance. The recall was initiated after the company detected microbial contamination during routine testing of subsequent unreleased product lots. An interaction between the product syringe and tamper-evident container closure was found. The company stated in a press release that this interaction may result in the potential introduction of microorganisms.

While the company has not yet received any complaints about adverse events, it warns that use of “non-sterile injection products that are intended to be sterile may result in a site-specific or systemic infection, which in turn may cause hospitalization, significant morbidity (permanent organ damage), or a fatal outcome.” 

Products affected by the recall, which were distributed nationwide to hospital pharmacies, clinics, and healthcare facilities, include the following:

  • Morphine Sulfate (Single Dose Syringe) 2mg/mL Preservative Free Injection

  • Morphine Sulfate (Single Dose Syringe) 4mg/mL Preservative Free Injection

  • Hydromorphone HCL (Single Dose Syringe) 1mg/mL Preservative Free Injection

  • Neostigmine Methylsulfate (Single Dose Syringe) 1mg/mL Injection.

More product information, including lot numbers and beyond use dates, can be found on FDA’s website.

Source: FDA

 

Recent Videos
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.